0000885590-12-000080.txt : 20121213 0000885590-12-000080.hdr.sgml : 20121213 20121213161736 ACCESSION NUMBER: 0000885590-12-000080 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121211 FILED AS OF DATE: 20121213 DATE AS OF CHANGE: 20121213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hanson Jason David CENTRAL INDEX KEY: 0001368586 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 121262310 MAIL ADDRESS: STREET 1: 8125 NORTH HAYDEN ROAD CITY: SCOTTSDALE STATE: AZ ZIP: 85258-2463 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4787 LEVY STREET STREET 2: MONTREAL CITY: QUEBEC STATE: A8 ZIP: H4R 2P9 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 4787 LEVY STREET STREET 2: MONTREAL CITY: QUEBEC STATE: A8 ZIP: H4R 2P9 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2012-12-11 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001368586 Hanson Jason David 4787 LEVY STREET MONTREAL A8 H4R 2P9 QUEBEC, CANADA 0 1 0 0 EVP, Company Group Chairman Non-Qualified Stock (right to purchase) 58.16 2012-12-11 4 A 0 84500 0 A 2016-12-11 2022-12-11 Common Shares, no par value 84500 84500 D Restricted Share Units 0 2012-12-11 4 A 0 36300 0 A Common Shares, no par value 36300 36300 D The options vest 25% per year for 4 years starting from the date of grant with the first vest date falling on the first anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant and the fourth vest date falling on the fourth anniversary of the grant. Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (3). The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $55.66 on each of three measurement dates: 25% would vest on September 11, 2015, 50% on December 11, 2015 and 25% on March 11, 2016, with early vesting possible at higher TSR levels. by: Nicholas Zanoni for Jason D. Hanson 2012-12-13